Understanding DMG: current treatment options and prospective solutions using nanoparticles Authors: Ahmed Mohamed, Aleksey Lyzlov, Rachna Prasad, Rex A. Moats, Mark D. Krieger, Virendra R. Desai, Ashley S. Margol, Peter A. Chiarelli, Meenakshi Upreti Published: 2026 ABSTRACT Diffuse Midline Gliomas (DMGs), which include the subset formerly known as Diffuse Intrinsic Pontine Glioma (DIPG), are associated with an extremely poor prognosis and a five-year survival rate below 2–3%. The devastating prognosis stems from an inherently invasive nature, a deep, anatomically restricted location, rapid cellular drug efflux mediated by transporters such as P-glycoprotein (ABCB1) and breast cancer resistance protein (BCRP/ABCG2), and an immunologically “cold” microenvironment. Coupled with limited Blood-Brain Barrier (BBB) permeability, these biological factors render conventional, therapeutic strategies minimally effective. Nanoparticles (NPs) offer novel opportunities to enhance drug delivery across the BBB by improving penetration—primarily through strategies such as receptor-mediated transcytosis or localized delivery approaches—thereby concentrating therapy at the tumor site, lowering systemic toxicity, and enabling integration of diagnostic imaging. Crucially, the distinct and targetable biology of this H3K27-altered disease, including alterations in ACVR1, PDGFRA, and CDK4/6 pathways, makes it a key focus for current nanomedicine research.This review evaluates how NP strategies have potential to provide adaptive solutions to overcome the hurdles in therapeutic development for DMG. It details the major NP platforms—including liposomal, polymeric, inorganic, and carbon-based nanomaterials— focusing on design principles like size, surface charge, and stealth coating to enhance targeted delivery for passive accumulation or receptor-mediated transport across the BBB. It explores theranostic applications that integrate real-time imaging (MRI, PET) with targeted, personalized therapy. Additionally, the role of high-Z metal NPs as radiosensitizers is discussed, highlighting their ability to increase DNA damage in tumor cells while protecting healthy tissue. Although early studies demonstrate strong in vitro efficacy, challenges in BBB penetration, intratumoral distribution and nanomaterial scaling still impede successful in vivo translation. Nanomedicine overcomes critical DMG barriers by enabling targeted, sustained, image-guided therapy. Achieving meaningful survival benefit for patients with DMG requires a multidisciplinary approach bridging neuro-oncology, advanced imaging, and nanomaterials development. Future research must prioritize four key areas: (1) optimizing NP properties for superior brainstem penetration, (2) leveraging DMG-specific markers for active delivery, (3) integrating theranostics for real-time monitoring, and (4) developing scalable, clinically compliant manufacturing. Introduction Diffuse Midline Glioma (DMG) is an aggressive, malignant, and currently incurable high-grade glioma primarily affecting children and adolescents. DMG is a broad diagnostic category for high-grade gliomas located in midline structures such as the thalamus, brainstem (pons), and spinal cord, representing 10–20% of all pediatric central nervous system (CNS) tumors. Diffuse Intrinsic Pontine Glioma (DIPG) is the term referred specifically to the subset of DMG located in the pons, typically estimated to account for 10–15% of pediatric CNS tumors. Prognosis remains poor with a median survival of approximately 8–11 months and a less than 2% survival in five years following initial diagnosis [1–6]. The rapid and infiltrative growth of DMG causes the sudden onset of a characteristic constellation of neurological symptoms associated with movement, speech, and swallowing, largely driven by brainstem involvement and compression of the corticospinal tracts. These include: cranial nerve palsies, long-tract signs (e.g., hyperreflexia, Babinski sign, motor deficits), and cerebellar dysfunction (e.g., ataxia, dysmetria) [7]. However, the precise location of the tumor dictates the patient’s symptoms (e.g., motor deficits result from lesions in the thalamus or spinal cord). Documented cases of extra-neural DMG metastasis exist but are exceedingly rare, with reported rates of ~ 0.4–2% in intracranial gliomas overall and only isolated case reports described in DMG [8–10]. Widespread intracranial spread has been reported, encompassing the brainstem (medulla/midbrain), cerebellum, thalamus, and leptomeninges [11, 12]. The molecular pathology of DMG (Fig. 1) is predominantly distinguished by a specific oncohistone mutation. According to the 2021 WHO CNS classification, this entity is defined as ‘Diffuse Midline Glioma, H3 K27-altered,’ encompassing both H3K27M mutations and cases with EZHIP overexpression that similarly disrupt histone methylation. The H3K27M mutation, a lysine-to-methionine substitution, occurs in the histone 3 genes H3F3A and HIST1H3B, which encode the H3.3 and H3.1 variants, respectively [13, 14]. This mutation inhibits the polycomb repressive complex 2 (PRC2), leading to a global loss of H3K27 trimethylation (H3K27me3) and subsequent transcriptional dysregulation. The resulting epigenetic changes promote unchecked cellular proliferation and tumor growth [15]. Beyond the defining or driver H3 K27M gene mutations crucial for tumor initiation, DMGs are further characterized by a complex mutational landscape that drives their development and aggressive progression (passenger gene mutations). Mutations in the tumor suppressor gene TP53 are of high prevalence, occurring in approximately 60–80% of cases, and frequently co-occur with H3.3 K27M alterations. This association is key to increased genomic instability, therapeutic resistance to radiation, and a significantly worse prognosis [1, 16–18]. Another frequent cooperating mutation occurs in the ACVR1 gene in approximately 20–30% of cases, typically found alongside H3.1 K27M mutations, which leads to the overactivation of the bone morphogenetic protein signaling pathway that blocks cell differentiation [19–21]. Amplifications and gain-of-function mutations in the receptor tyrosine kinase gene PDGFRA are also found in 14–21% of cases, promoting cell proliferation and survival by activating downstream signaling pathways like PI3K/AKT/mTOR and Ras/Raf/MEK/ERK [22–24]. Additionally, truncating mutations in the phosphatase-encoding gene PPM1D are found in a subset of DMGs, suppressing the p53-dependent DNA damage response and enhancing tumorigenesis [25]. Aberrations in cell cycle regulators, such as amplifications of CCND family members and CDK4/6, lead to bypassing of normal cell cycle control and drive unchecked proliferation [26]. Finally, mutations in the chromatin remodeling gene ATRX are also observed in some DMGs and contribute to genomic instability, though they are less frequent in H3 K27M tumors than in other pediatric gliomas [13]. Beyond the established drivers, emerging evidence suggests that mutations in PARP1 may contribute to DMG pathogenesis. Although their precise impact on DNA repair mechanisms is still exploratory, they underline the complex molecular landscape of this malignancy [27]. Furthermore, in a subset of DMGs (~ 4%) lacking the H3 K27M mutation, aberrant overexpression of enhancer of zeste homolog 2 inhibitory protein (EZHIP) from the CXorf67 gene has been observed. This overexpression mimics the effect of the oncohistone by inhibiting the PRC2 pathway (driver mutation), which in turn leads to global genome remodeling and a similar loss of H3K27 trimethylation [28]. Fig. 1The Evolving Molecular Landscape of DMG Progression. Driver mutations fuel tumor development, while passenger mutations act as hitchhikers accumulating during tumor evolution. The figure highlights key temporal changes from diagnosis to recurrence, including Driver and Passenger mutations, and clonal evolution The Evolving Molecular Landscape of DMG Progression. Driver mutations fuel tumor development, while passenger mutations act as hitchhikers accumulating during tumor evolution. The figure highlights key temporal changes from diagnosis to recurrence, including Driver and Passenger mutations, and clonal evolution Given the genomic landscape and poor prognosis of DMG, a better understanding of the tumor microenvironment (TME) is crucial for developing effective therapeutic strategies. Research indicates that DMG fosters a unique microenvironment that differs significantly from other high-grade gliomas (Fig. 2). They show an increase in immunosuppressive cells like regulatory T (Treg) cells and neutrophils, but a decrease in anti-tumor cells such as CD8 + T cells and natural killer (NK) cells. Characterized as an immunologically ‘cold’ microenvironment, this response often shows limited T cell presence, while findings on neutrophil infiltration remain variable across studies. This imbalance is critical, as a higher neutrophil count in the TME is specifically linked to poor prognosis for the patient [29, 30]. Immunohistochemical studies to further characterize the immune landscape reveal significantly reduced infiltration of CD163 + and CD68 + macrophages in DMG compared to both high- and low-grade gliomas, with some studies instead identifying a predominance of resident microglia-derived myeloid populations [31]. Similar, flow cytometry data confirmed a lower abundance of CD3 + lymphocytes and an increased presence of CD11b+ myeloid cells in DMG compared to adult glioblastoma (GBM) [30]. The expression of cytokines and immune checkpoint inhibitors in DMG also deviates from other gliomas. Fig. 2Schematic displaying the unique TME of DMG. Schematic displaying the unique TME of DMG with decreased infiltration of common tumor immune mediators such as neutrophils, CD8 + T cells, and natural killer cells in comparison to other High Grade Gliomas Schematic displaying the unique TME of DMG. Schematic displaying the unique TME of DMG with decreased infiltration of common tumor immune mediators such as neutrophils, CD8 + T cells, and natural killer cells in comparison to other High Grade Gliomas Studies have shown that PD-L1 levels are similar or even decreased, and there is no significant increase in the expression of immune checkpoints such as PD-1, PD-L2, or CTLA-4 [30–32]. The observed scarcity of these immune mediators suggests a uniquely immune-suppressive environment in DMG. While the DMG TME remains under investigation, Fig. 2 illustrates that the decreased infiltration of T cells, macrophages, and key cytokines, along with low immune checkpoint expression (≤ 1%) relative to other HGGs like GBM (~ 60%), offers a plausible explanation for the aggressive nature of DMG and the limited efficacy of checkpoint inhibitor therapies [30–32]. This suggests a promising new treatment pathway that focuses on strategies to increase the recruitment of these specific cell types to the tumor site. The inability of historical clinical trials to improve patient outcomes necessitates a rigorous evaluation of past therapeutic strategies to guide future innovation. To address the ongoing challenges in DMG treatment, this review will perform a three-part analysis. First, we will examine the evolution of DMG treatment strategies, tracing the trajectory from foundational therapeutic approaches to current emerging targeted and immunotherapeutic interventions under investigation. Next, we will analyze the application of nanoparticles (NPs) in brain cancers to understand their potential and limitations. Finally, we will explore how the emergent field of nano-scaled materials offers avenues for improving DMG therapy, guided imaging, and diagnosis. Managing diagnostic approach and standard-of-care for DMG Diagnosis of DMG in non-brainstem locations can benefit from surgical biopsy when required, while diagnosis of pontine DMG is frequently established by correlating the patient’s clinical history and characteristic radiologic findings with biopsy serving a more nuanced role. The Magnetic Resonance Imaging (MRI) typically demonstrates (Fig. 3) a diffusedly infiltrative lesion involving > 50% of the pons, with associated expansion, a hypointense signal on T1-weighted images, a hyperintense signal on T2-weighted images and encasement of the basilar artery [33, 34]. While contrast uptake or rim enhancing portions of the mass may be present, a notable lack of enhancement after gadolinium contrast administration, is what differentiates DMG from other CNS tumors [35]. Fig. 3MRI-based radiomics for prognosis of a pediatric H3 K27-altered DMG (Courtesy Neurosurgery, Children’s Hospital Los Angeles) (A) T1-weighted pre-contrast axial MRI: infiltrative, expansile tumor in pons, slightly hypointense with mass effect on fourth ventricle (*) (B) T2-weighted axial MRI: slightly hyperintense signal throughout the tumor (C) T1 post-contrast axial MRI: minimal to no enhancement. The hyperintense and hypointense in MRI scans describe the relative brightness of the tumor tissue compared to the surrounding or normal brain tissue MRI-based radiomics for prognosis of a pediatric H3 K27-altered DMG (Courtesy Neurosurgery, Children’s Hospital Los Angeles) (A) T1-weighted pre-contrast axial MRI: infiltrative, expansile tumor in pons, slightly hypointense with mass effect on fourth ventricle (*) (B) T2-weighted axial MRI: slightly hyperintense signal throughout the tumor (C) T1 post-contrast axial MRI: minimal to no enhancement. The hyperintense and hypointense in MRI scans describe the relative brightness of the tumor tissue compared to the surrounding or normal brain tissue While surgical biopsy for classically appearing DMG was historically controversial, stereotactic biopsy has become increasingly accepted in modern clinical practice, with reported overall complication rates of approximately 5–10% in experienced centers [36–39]. This paradigm shift is driven by three main factors: (i) the use of molecular genomics to identify actionable target mutations, (ii) the requirement of tissue for clinical trial enrollment, and (iii) enhanced safety profiles in modern neurosurgical stereotaxis, which has significantly reduced the morbidity and mortality rates reported in previous decades [40–42]. Despite these advances, the procedure remains risky for pediatric patients. To address this, liquid biopsy of blood and cerebrospinal fluid (CSF) has emerged as a safer, minimally invasive method for monitoring tumor evolution via circulating tumor DNA (ctDNA) [43–46]. Although pontine DMG is not surgically resectable, the role of resection or debulking for non-brainstem DMG remains to be established. Such procedures require careful evaluation of involved structures and a balance of risks versus benefits, particularly considering the limited outcomes data for H3K27M-mutated tumors. Treatment efficacy is severely limited because most therapeutics, particularly chemotherapy, cannot effectively reach the tumor site [36]. This is primarily due to the blood-brain barrier (BBB), which is especially restrictive in the pons where 80% of H3 K27-altered DMGs originate [47] and where drug efflux transporters are also present, further reducing drug concentration [48]. The unique DMG microenvironment and potential anisotropic effects following chemotherapy which decreases the agents’ diffusional capacity also contribute to making conventional cancer treatments ineffective [49]. Radiotherapy has been the mainstay of treatment for DMG since the 1970s. Current standard of care includes fractionated focal radiation—typically 54–60 Gy over six weeks—using techniques such as intensity-modulated radiation therapy (IMRT). While this approach can provide symptomatic and quality of life improvements with temporary reduction in tumor size, disease progression usually occurs within six months, with an estimated survival advantage quoted as approximately three months [50, 51]. Both hypo-fractionation and hyper-fractionation of radiation therapy for DMG have failed to improve survival rates. Doses below 50 Gy are linked to worse outcomes, while doses above 66 Gy offer no additional survival benefit [52, 53]. Re-irradiation of progressive tumors shows promise, although increased risk of cumulative radiation necrosis must be considered when weighing the value of this treatment option [54–56]. Supportive treatment often includes corticosteroids to manage peri-tumoral edema (brain swelling). While 70–80% of patients see some neurological improvement from corticosteroids, over 50% experience significant side effects from the medication [57]. Therapeutic strategies in dmg clinical trials Chemotherapy Traditional chemotherapies, including cisplatin [58], carboplatin [59], temozolomide [60], motexafin gadolinium [2], tamoxifen [61], and methotrexate [62], have failed to improve survival outcomes in DMG, whether used alone, in combination, or alongside radiotherapy. Clinical trials consistently report a median overall survival (OS) of 9–11 months (Table 1), showing no significant advantage over radiation therapy alone, which yields median OS rates of 12.0, 10.2, and 7.9 months for conventional, hyperfractionated, and hypofractionated regimens, respectively [63]. This lack of success is likely due to a combination of inadequate drug delivery and factors within the TME [2, 50, 60, 64-72]. Table 1Summary of survival metrics comparing radiation and chemoradiation trials for DMGTreatment regimenMedian overall survivalRadiation therapy (RT)7.9 - 12.0 monthsRT + Cisplatin8.5 monthsRT + carboplatin9 monthsRT + Temozolomide9.6 monthsRT + Motexafin gadolinium8.4 monthsRT + Tamoxifen6.31 monthsRT + Methotrexate12.5 months Table 1Summary of survival metrics comparing radiation and chemoradiation trials for DMGTreatment regimenMedian overall survivalRadiation therapy (RT)7.9 - 12.0 monthsRT + Cisplatin8.5 monthsRT + carboplatin9 monthsRT + Temozolomide9.6 monthsRT + Motexafin gadolinium8.4 monthsRT + Tamoxifen6.31 monthsRT + Methotrexate12.5 months Summary of survival metrics comparing radiation and chemoradiation trials for DMG Targeted drug therapies for DMG patients have shown promise. Recent advances include dordaviprone (formerly ONC201, brand name Modeyso), which received accelerated FDA approval in August 2025 for treating progressive H3 K27M-mutant DMG based on surrogate endpoints in a relapsed setting. However, this approval is conditional, and long-term survival benefit remains under investigation in the Phase 3 clinical trial (NCT05580562), which is currently evaluating which is currently evaluating dordaviprone efficacy in newly diagnosed patients. The oral imipridone medication works by antagonizing the dopamine receptor D2 (DRD2) and acting as an agonist for the mitochondrial protease ClpP. The mechanism of imipridone action involves activation of the integrated stress response, which leads to selective apoptosis in cancer cells [73]. The PI3K/AKT/mTOR signaling pathway is frequently dysregulated in DMG, making it a target for therapy. Approximately 15–20% DMG cases present mutations in phosphatidylinositol 3-kinase (PIK3CA) gene. Current therapeutic strategies include testing the mTOR inhibitor, Everolimus and PI3K inhibitor, Paxalisib, in combination with other agents (e.g. NCT03387020, NCT05009992, NCT05843253) [74]. Fig. 4 summarizes the available DMG management strategies, including a comparison of their benefits and drawbacks. Fig. 4Current and Emerging Management Strategies for DMG: Overview of current (radiation, surgical resection, chemotherapy) and investigational (immunotherapy, next generation) strategies (Purple), showcasing their efficacy and constraints (Pink) and their mechanisms (Blue) in DMG management Current and Emerging Management Strategies for DMG: Overview of current (radiation, surgical resection, chemotherapy) and investigational (immunotherapy, next generation) strategies (Purple), showcasing their efficacy and constraints (Pink) and their mechanisms (Blue) in DMG management CAR T cell therapy The field of cancer immunotherapy has advanced significantly, leveraging the patient’s own immune system to combat malignancy. A well accepted strategy involves chimeric antigen receptor (CAR) T-cell therapy, which has achieved notable success in hematologic cancers and is currently being explored for solid tumors. CAR T cells are genetically engineered to express synthetic receptors that bind to specific tumor antigens, providing a mechanism to overcome the ability of cancer cells to escape attack by the innate immune system. Targeting the disialoganglioside GD2 with CAR T cells has emerged as a promising strategy for glioma therapy. Due to its selective overexpression in the malignant tissue of several cancer types and minimal presence in healthy tissue, GD2 serves as an ideal tumor-associated antigen. Despite being a small cohort of patients, a recent study focusing on H3 K27-mutated gliomas (NCT04196413) demonstrates the potential of GD2 directed CAR T cell therapy to induce significant clinical and radiographic improvements with tumor shrinkage of 50–98% observed in 7 of 11 patients and a median survival approaching 2 years, substantially exceeding historical expectations [75]. B7-H3, a transmembrane protein overexpressed on DMG cells, has also emerged as a viable target for CAR-T cell therapy. Engineered constructs directed against this molecule are now being evaluated in clinical trials [76]. Furthermore, the IL13Rα2 antigen is found to be overexpressed on about half of all pediatric brain tumors. A CAR T-cell therapy trial (NCT04510051) specifically targeting IL13Rα2-positive, recurrent or refractory pediatric brain tumors posted on August 12, 2020 is also recruiting children with DMG [77]. However, CAR T-cell therapy for DMG carries critical safety risks, including cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), tumor-inflammation associated neurotoxicity (TIAN) and oedema. These can lead to pseudoprogression and severe increased intracranial pressure. Furthermore, on-target, off-tumor effects remain a significant concern due to potential antigen expression on healthy CNS tissue, necessitating the need for careful patient monitoring and specialized supportive management [75, 78]. Vaccines The rationale for using vaccines in pediatric brain tumors is to harness the immune system to fight cancer cells with greater specificity and reduced toxicity compared to traditional therapies [79]. After administration of autologous dendritic cell vaccines that activate T-cells, one clinical trial demonstrated a DIPG/DMG-specific immune response [80]. Similar anti-tumor responses have also been observed in small patient studies using the immune antibody Pidilizumab and genetically modified adenoviruses [81, 82]. An ongoing phase I clinical trial (NCT04943848) is testing a neoantigen peptide-based vaccine—combining a heat shock protein with 16 H3 K27-altered DMG-specific peptides—to evaluate its ability to boost immune recognition of tumor cells. While these results show potential, expanding patient cohorts and mitigation of adverse effects are necessary to facilitate clinical translation for DMG treatment. Image-guided noninvasive therapies Novel, image-guided multi-modal strategies are emerging to selectively target malignant tumors. Among these, sonodynamic therapy (SDT), combines low-intensity ultrasound with a prodrug, 5-aminolaevulinic acid (5-ALA) to target tumors. 5-ALA serves as a prodrug that preferentially accumulates in rapidly dividing tumor cells, where it is metabolized into the photosensitizer protoporphyrin IX (PpIX) by disrupting the heme biosynthetic pathway while sparing the healthy tissue. Subsequent excitation of PpIX by MRI-guided focused ultrasound generates cytotoxic reactive oxygen species (ROS), triggering apoptosis. Pre-clinical results from animal models showed inhibition of tumor growth and extended survival [83, 84]. Following a successful Phase 0/1 safety trial (NCT04559685) [85], a Phase 2 study (NCT05123534) is currently underway to optimize protocols and evaluate clinical efficacy in DMG. Table 2 summarizes the major treatment strategies in clinical trial in the United States for DMG, including associated benefits and pitfalls [86, 87]. Although some of these strategies have shown preclinical therapeutic efficacy, none have yet demonstrated considerable survival improvement for patients. Table 2Summary of Ongoing and Completed Clinical Trials including DMG Patients [86, 87] Detailed description of the therapeutic/trials, including phase, ClinicalTrials.gov identifier, administration, mechanism, & indicationActive TrialsDrug/Trial #NCT#PhaseRoute of AdministrationAge GroupMolecular Target/MechanismIndication(s)ImmunotherapyAPX005MNCT03389802IIVPediatricsCD40 AgonistDMG,Recurrent/refractory CNS tumorsB7-H3 CAR-TNCT04185038IIntracranialPediatricsYoung AdultsB7-H3DMGRecurrent/refractory CNS tumorsB7-H3, EGFR806, HER2, & IL13-Zetakine (Quad) CAR T CellsNCT05768880IIntracranialPediatricsYoung AdultsB7-H3EGFR806HER2IL13Rα2DMG,Recurrent/refractory CNS tumorsC7R-GD2.CAR T CellsNCT04099797IIV ± IntracranialPediatricsYoung AdultsGD2GD2-expressing brain tumorsGD2 CAR T CellsNCT05298995IIntracranialPediatricsYoung AdultsGD2GD2-expressing brain tumorsLoc3CARNCT05835687IIVPediatricsPD-1/PD-L1 axisPrimary CNS tumorsPembrolizumabNCT02359565IIVPediatricsYoung AdultsPD-1 pathwayDMG, Medulloblastoma, Refractory HGG, EpendymomaPNOC018NCT05478837IIntracranialPediatricsYoung AdultsCAR-TH3.3K27M-Mutated GliomaReMINDNCT03652545IIVPediatricsAdultsWT1, PRAME, & survivin tumor-associated antigensCNS malignancies (including DMG)Targeted TherapyAbemaciclibNCT02644460IPOPediatricsYoung AdultsmTOR pathwayDMGAbemaciclibNCT05298995IIntracranialPediatricsYoung AdultsGD2DMGSolid brain/spinal tumorsACT001NCT06838676IPOPediatricsPI3K/AKT/mTOR pathwayDMGHGGAflacST1901NCT04334863IPOPediatricsPI3K/mTORRecurrent/ progressive malignant brain tumors, MelanomaCLR 131NCT03433183IPOPediatricsCDK4/6Relapsed/refractory solid & brain tumors LymphomaFimepinostatNCT03893487IPOPediatricsYoung AdultsHDAC inhibitorDMG, Medulloblastoma,HGGLarotrectinibNCT04655404IPOPediatricsDRD2 antagonist/DIpP agonistHGGMarizomab + PanobinostatNCT04341311IPOPediatricsEZH2DMGONC206NCT04732065IPOPediatricsYoung AdultsDNA damage/PARP pathwayDMG,Recurrent malignant CNS tumorsPrecision Medicine and Adoptive Cellular Therapy (PEACH)NCT04837547IPOPediatricsYoung AdultsMAPK/MEK pathwayDMGRecurrent neuroblastomaSavolitinib(PBTC49)NCT03598244IPOPediatricKinase inhibitionDMG, MedulloblastomaHGG9-ING-41 +/- irinotecanNCT04239092I/IIPOPediatricsYoung AdultsEpigenetic modulationRefractory CNS tumorsAvapritinibNCT04773782I/IIPOPediatricsKinase inhibitionRelapsed/refractory solid tumorsCabozantinibNCT02885324I/IIPOPediatricsHistone modificationRecurrent/ progressive malignant brain tumorsCBL0137NCT01981525I/IIPOPediatricsTargeted kinase pathwayProgressive/refractory CNS tumors, LymphomaLutatheraNCT05278208I/IIPOPediatricsYoung AdultsVEGFCNS tumorsMeningiomasOral AMXT 1501 Dicaprate + IV DFMONCT05500508I/IIPOPediatricsPI3K/AKT pathwayDMGRibociclib + EverolimusNCT03387020I/IIPOPediatricsYoung AdultsCDK4/6DMGONC201 + Panobinostat or PaxalisibNCT05009992IIIV ± Image-guided deliveryPediatricsYoung AdultsDrug delivery enhancementradiosensitizationDMGONC201 Following Radiotherapy (ACTION)NCT05580562IIIPOPediatricsAdultsTargeted small-molecule therapyDMGChemotherapyBXQ-350NCT04771897IIVPediatricsCytotoxicDMGGemcitabineNCT02992015IIVPediatricsDNA synthesis inhibitionDMGUnesbulinNCT03605550IOral ± IVPediatricsAlkylating agentDMG, HGGPediatric MATCH trialNCT03155620IIIVPediatricsCytotoxicSolid tumors, NHLHistiocytic disordersHIT-HGG-2013NCT03243461IIIIVPediatricsCytotoxicGBM, Anaplastic astrocytoma DMG, Gliomatosis cerebriRadiationStereotactic Biopsy Split-CourseRadiation TherapyNCT05077735IIExternal beam radiationPediatricsDNA damageDMGVaccinePEP-CMVNCT03299309IIntradermal/subQPediatricsYoung AdultsTumor-specific neoantigensMedulloblastomaGrade III or IV gliomasSurVaxM(PBTC-060)NCT05163080IIntradermalPediatricsTumor antigen-specific immune activationMedulloblastoma, Astrocytoma, DMG, GBM, Oligodendroglioma, EpendymomaImage-Guided TherapyExablate Focused Ultrasound + DoxorubicinNCT05009992I/IIImage-guided; IVPediatricsYoung AdultsDrug delivery enhancementDMGMTX110 delivered by convection-enhanced delivery (CED)NCT03566199I/IIConvection-enhanced delivery (CED); intracranialPediatricsYoung AdultsLocal drug deliveryDMGSONALA-001 + Exablate 4000 Type 2.0NCT05123534IIOral + MRI-guided ultrasoundPediatricsYoung AdultsROS generationDMGCombinationAdavosertib + Local Radiation TherapyNCT01922076IIV + radiationPediatricsChemo-radiationDMGAdoptive Cellular Therapy During Focal Radiotherapy +/- TemozolomideNCT03396575IPO + radiationPediatricsYoung AdultsTargeted + radiation synergyBrainstem gliomasConvection-Enhanced Delivery (CED) of MTX110NCT03566199ICEDPediatricsLocal deliveryDMGFocused Ultrasound (FUS) + oral panobinostatNCT04804709IPO + IVPediatricsMulti-pathway inhibitionDMGFUS EtoposideNCT05762419IPO + immunotherapyPediatricsTargeted + immune therapyDMGHSC-DIPGVax + Balstilimab + ZalifrelimabNCT04943848IIntradermalPediatricsH3K27M neoantigen vaccineDMGVorinostat + Temsirolimus +/- RadiationNCT02420613IIVPediatricsChemotherapyDMGAbemaciclib (LY2835219) + temozolomide +/- irinotecan, Dinutuximab, GM-CSFNCT04238819I/IIPOPediatricsTargeted + epigeneticRelapsed/refractory solid tumorsNeuroblastomaH3.3K27M Peptide Vaccine + NivolumabNCT02960230I/IIIVPediatricsYoung AdultsChemotherapy + radiationDMGOptune device + radiationNCT03033992I/IIPOPediatricsYoung AdultsTargeted therapy combinationHGG, EpendymomaDMGPalbociclib + ChemotherapyNCT03526250I/IIPOPediatricsYoung AdultsMulti-pathway inhibitionRecurrent/refractory solid tumorsREGN2810 + RadiotherapyNCT03690869I/IIPO + IVPediatricsTargeted + chemotherapyRelapsed/refractory solid or CNS tumorsSelinexor + Radiation TherapyNCT05099003I/IIPOPediatricsYoung AdultsTargeted TherapyHGGDMGIndoximod + Chemotherapy + RadiationNCT04049669IIPOPediatricsYoung AdultsTargeted TherapyProgressive brain tumorsDMGMethotrexate + radiationNCT00278278IIIVPediatricsChemotherapyHGG, DMG Completed Trials ImmunotherapyWild-type reovirus + sargramostimNCT02444546IIVPediatricsPD-1Recurrent/refractory brain tumorsPomalidomideNCT03242460I/IIIVPediatricsYoung AdultsPD-1/CTLA-4Recurrent/progressive CNS tumorsPegylated Interferon Alfa 2bNCT07231276IIIVPediatricsImmune checkpoint modulationDMGTargeted TherapyAbemaciclibNCT05413304IIntracranialPediatrics, Young AdultsCAR-T/tumor-associated antigenRecurrent/refractory solid/brain tumors, DMGCrenolanibNCT01522469IIVPediatrics,Young AdultsPD-1/PD-L1 axisDMGHGGCrizotinib + DasatinibNCT01644773IIVPediatricsCTLA-4DMGHGGGDC-0084NCT03696355IIVPediatricsPD-1 checkpoint inhibitionDMGINCB7839NCT04295759IIVPediatricsImmune checkpoint inhibition/T-cell activationHGG, DMGPanobinostatNCT02717455IIVPediatricsImmune checkpoint pathwayDMGRecurrent/progressive HGGRibociclib + EverolimusNCT05843253IIVPediatricsYoung AdultsImmune modulationDMGHGGAd-RTS-hIL-12 + VeledimexNCT03330197I/IIIVPediatricsYoung AdultsImmune checkpoint/cytokine modulationDMGPanobinostat (MTX100)NCT03566199I/IICEDPediatricsLocal drug deliveryDMGDepatuxizumab Mafoditin (ABT-414) +/- Temozolomide or LomustineNCT02343406IIPOPediatricsAdultsTargeted kinase inhibitionEGFR-amplified gliomasChemotherapyMebendazoleNCT02644291IPOPediatricsTargeted small-molecule therapyPediatric gliomasIntra-arterial delivery of Melphalan HydrocholorideNCT01688401I/IIIVPediatricsVEGFRecurrent/refractory CNS tumorsMebendazole + vincristine, carboplatin, and temozolomideNCT01837862I/IIPOPediatricsKinase pathwayLGG, HGGTrametinib +/- DabrafenibI/IIPediatricsMAPK pathwayRelapsed/refractory cancerNivolumab +/- IpilumumabNCT03130959IIPOPediatricsYoung AdultsEpigenetic modulationHigh grade CNS tumorsNimotuzumabII/IIIPediatricsDMGRadiationFinding maximum dose of reirradiationNCT02709226I/IIPOPediatricsTargeted DNA damageDMGHypofractionatedRadiotherapyNCT05077735IIExternal beam radiationPediatricsDNA damageDMGRe-irridation of progressive orrecurrent DMGIIPediatricsAdultsTargeted DNA damageDMGRe-irradiation versus RT and Multiple elective RT coursesNCT03620032IIPOPediatricsYoung AdultsTargeted DNA DamageDMGVaccinesImmune Modulatory DC VaccineNCT03914768IPOPediatricsAdultsTargeted kinase pathwayGBMDMGImage-Guided TherapyCED of 124I-omburtamabNCT01502917ICEDPediatricsChemotherapyDMGCombinationBevacizumab +/- temozolomide +/- irinotecanNCT01114555I/IICEDPediatricsCytotoxic Drug DeliveryDMGHGGIndoximod + TemozolomideNCT04049669I/IIPOPediatricsTargeted TherapyDMGRecurrent/refractory CNS tumorsIrinotecan Liposome Injection using real time imaging w/ gadoliniumNCT03088813ICEDPediatricsLocal Drug DeliveryDMGLenalidomide + radiationNCT01226940IIVPediatricsChemotherapyDMG, HGGTemozolomide + radiationNCT05009992I/IIIV ± image-guidedPediatricsDrug delivery/RadiosensitizationDMGValproic acid, radiation, and bevacizumabNCT00879437IIIVPediatricsCytotoxic ChemotherapyDMG, HGGVandetanib + Dasatinib + radiationNCT00996723IIVPediatricsChemotherapyDMGVorinostat + radiationNCT01189266I/IIPOPediatricsKinase inhibitionDMGMindfulness-based InterventionNCT05336916N/AIVPediatrics, Young AdultsImmunotherapy/checkpoint modulationDMGHigh risk cancersHGG (high grade glioma) | MB (medulloblastoma) | GBM (glioblastoma multiforme) | NHL (Non-Hodgkin Lymphoma) Table 2Summary of Ongoing and Completed Clinical Trials including DMG Patients [86, 87] Detailed description of the therapeutic/trials, including phase, ClinicalTrials.gov identifier, administration, mechanism, & indicationActive TrialsDrug/Trial #NCT#PhaseRoute of AdministrationAge GroupMolecular Target/MechanismIndication(s)ImmunotherapyAPX005MNCT03389802IIVPediatricsCD40 AgonistDMG,Recurrent/refractory CNS tumorsB7-H3 CAR-TNCT04185038IIntracranialPediatricsYoung AdultsB7-H3DMGRecurrent/refractory CNS tumorsB7-H3, EGFR806, HER2, & IL13-Zetakine (Quad) CAR T CellsNCT05768880IIntracranialPediatricsYoung AdultsB7-H3EGFR806HER2IL13Rα2DMG,Recurrent/refractory CNS tumorsC7R-GD2.CAR T CellsNCT04099797IIV ± IntracranialPediatricsYoung AdultsGD2GD2-expressing brain tumorsGD2 CAR T CellsNCT05298995IIntracranialPediatricsYoung AdultsGD2GD2-expressing brain tumorsLoc3CARNCT05835687IIVPediatricsPD-1/PD-L1 axisPrimary CNS tumorsPembrolizumabNCT02359565IIVPediatricsYoung AdultsPD-1 pathwayDMG, Medulloblastoma, Refractory HGG, EpendymomaPNOC018NCT05478837IIntracranialPediatricsYoung AdultsCAR-TH3.3K27M-Mutated GliomaReMINDNCT03652545IIVPediatricsAdultsWT1, PRAME, & survivin tumor-associated antigensCNS malignancies (including DMG)Targeted TherapyAbemaciclibNCT02644460IPOPediatricsYoung AdultsmTOR pathwayDMGAbemaciclibNCT05298995IIntracranialPediatricsYoung AdultsGD2DMGSolid brain/spinal tumorsACT001NCT06838676IPOPediatricsPI3K/AKT/mTOR pathwayDMGHGGAflacST1901NCT04334863IPOPediatricsPI3K/mTORRecurrent/ progressive malignant brain tumors, MelanomaCLR 131NCT03433183IPOPediatricsCDK4/6Relapsed/refractory solid & brain tumors LymphomaFimepinostatNCT03893487IPOPediatricsYoung AdultsHDAC inhibitorDMG, Medulloblastoma,HGGLarotrectinibNCT04655404IPOPediatricsDRD2 antagonist/DIpP agonistHGGMarizomab + PanobinostatNCT04341311IPOPediatricsEZH2DMGONC206NCT04732065IPOPediatricsYoung AdultsDNA damage/PARP pathwayDMG,Recurrent malignant CNS tumorsPrecision Medicine and Adoptive Cellular Therapy (PEACH)NCT04837547IPOPediatricsYoung AdultsMAPK/MEK pathwayDMGRecurrent neuroblastomaSavolitinib(PBTC49)NCT03598244IPOPediatricKinase inhibitionDMG, MedulloblastomaHGG9-ING-41 +/- irinotecanNCT04239092I/IIPOPediatricsYoung AdultsEpigenetic modulationRefractory CNS tumorsAvapritinibNCT04773782I/IIPOPediatricsKinase inhibitionRelapsed/refractory solid tumorsCabozantinibNCT02885324I/IIPOPediatricsHistone modificationRecurrent/ progressive malignant brain tumorsCBL0137NCT01981525I/IIPOPediatricsTargeted kinase pathwayProgressive/refractory CNS tumors, LymphomaLutatheraNCT05278208I/IIPOPediatricsYoung AdultsVEGFCNS tumorsMeningiomasOral AMXT 1501 Dicaprate + IV DFMONCT05500508I/IIPOPediatricsPI3K/AKT pathwayDMGRibociclib + EverolimusNCT03387020I/IIPOPediatricsYoung AdultsCDK4/6DMGONC201 + Panobinostat or PaxalisibNCT05009992IIIV ± Image-guided deliveryPediatricsYoung AdultsDrug delivery enhancementradiosensitizationDMGONC201 Following Radiotherapy (ACTION)NCT05580562IIIPOPediatricsAdultsTargeted small-molecule therapyDMGChemotherapyBXQ-350NCT04771897IIVPediatricsCytotoxicDMGGemcitabineNCT02992015IIVPediatricsDNA synthesis inhibitionDMGUnesbulinNCT03605550IOral ± IVPediatricsAlkylating agentDMG, HGGPediatric MATCH trialNCT03155620IIIVPediatricsCytotoxicSolid tumors, NHLHistiocytic disordersHIT-HGG-2013NCT03243461IIIIVPediatricsCytotoxicGBM, Anaplastic astrocytoma DMG, Gliomatosis cerebriRadiationStereotactic Biopsy Split-CourseRadiation TherapyNCT05077735IIExternal beam radiationPediatricsDNA damageDMGVaccinePEP-CMVNCT03299309IIntradermal/subQPediatricsYoung AdultsTumor-specific neoantigensMedulloblastomaGrade III or IV gliomasSurVaxM(PBTC-060)NCT05163080IIntradermalPediatricsTumor antigen-specific immune activationMedulloblastoma, Astrocytoma, DMG, GBM, Oligodendroglioma, EpendymomaImage-Guided TherapyExablate Focused Ultrasound + DoxorubicinNCT05009992I/IIImage-guided; IVPediatricsYoung AdultsDrug delivery enhancementDMGMTX110 delivered by convection-enhanced delivery (CED)NCT03566199I/IIConvection-enhanced delivery (CED); intracranialPediatricsYoung AdultsLocal drug deliveryDMGSONALA-001 + Exablate 4000 Type 2.0NCT05123534IIOral + MRI-guided ultrasoundPediatricsYoung AdultsROS generationDMGCombinationAdavosertib + Local Radiation TherapyNCT01922076IIV + radiationPediatricsChemo-radiationDMGAdoptive Cellular Therapy During Focal Radiotherapy +/- TemozolomideNCT03396575IPO + radiationPediatricsYoung AdultsTargeted + radiation synergyBrainstem gliomasConvection-Enhanced Delivery (CED) of MTX110NCT03566199ICEDPediatricsLocal deliveryDMGFocused Ultrasound (FUS) + oral panobinostatNCT04804709IPO + IVPediatricsMulti-pathway inhibitionDMGFUS EtoposideNCT05762419IPO + immunotherapyPediatricsTargeted + immune therapyDMGHSC-DIPGVax + Balstilimab + ZalifrelimabNCT04943848IIntradermalPediatricsH3K27M neoantigen vaccineDMGVorinostat + Temsirolimus +/- RadiationNCT02420613IIVPediatricsChemotherapyDMGAbemaciclib (LY2835219) + temozolomide +/- irinotecan, Dinutuximab, GM-CSFNCT04238819I/IIPOPediatricsTargeted + epigeneticRelapsed/refractory solid tumorsNeuroblastomaH3.3K27M Peptide Vaccine + NivolumabNCT02960230I/IIIVPediatricsYoung AdultsChemotherapy + radiationDMGOptune device + radiationNCT03033992I/IIPOPediatricsYoung AdultsTargeted therapy combinationHGG, EpendymomaDMGPalbociclib + ChemotherapyNCT03526250I/IIPOPediatricsYoung AdultsMulti-pathway inhibitionRecurrent/refractory solid tumorsREGN2810 + RadiotherapyNCT03690869I/IIPO + IVPediatricsTargeted + chemotherapyRelapsed/refractory solid or CNS tumorsSelinexor + Radiation TherapyNCT05099003I/IIPOPediatricsYoung AdultsTargeted TherapyHGGDMGIndoximod + Chemotherapy + RadiationNCT04049669IIPOPediatricsYoung AdultsTargeted TherapyProgressive brain tumorsDMGMethotrexate + radiationNCT00278278IIIVPediatricsChemotherapyHGG, DMG Completed Trials ImmunotherapyWild-type reovirus + sargramostimNCT02444546IIVPediatricsPD-1Recurrent/refractory brain tumorsPomalidomideNCT03242460I/IIIVPediatricsYoung AdultsPD-1/CTLA-4Recurrent/progressive CNS tumorsPegylated Interferon Alfa 2bNCT07231276IIIVPediatricsImmune checkpoint modulationDMGTargeted TherapyAbemaciclibNCT05413304IIntracranialPediatrics, Young AdultsCAR-T/tumor-associated antigenRecurrent/refractory solid/brain tumors, DMGCrenolanibNCT01522469IIVPediatrics,Young AdultsPD-1/PD-L1 axisDMGHGGCrizotinib + DasatinibNCT01644773IIVPediatricsCTLA-4DMGHGGGDC-0084NCT03696355IIVPediatricsPD-1 checkpoint inhibitionDMGINCB7839NCT04295759IIVPediatricsImmune checkpoint inhibition/T-cell activationHGG, DMGPanobinostatNCT02717455IIVPediatricsImmune checkpoint pathwayDMGRecurrent/progressive HGGRibociclib + EverolimusNCT05843253IIVPediatricsYoung AdultsImmune modulationDMGHGGAd-RTS-hIL-12 + VeledimexNCT03330197I/IIIVPediatricsYoung AdultsImmune checkpoint/cytokine modulationDMGPanobinostat (MTX100)NCT03566199I/IICEDPediatricsLocal drug deliveryDMGDepatuxizumab Mafoditin (ABT-414) +/- Temozolomide or LomustineNCT02343406IIPOPediatricsAdultsTargeted kinase inhibitionEGFR-amplified gliomasChemotherapyMebendazoleNCT02644291IPOPediatricsTargeted small-molecule therapyPediatric gliomasIntra-arterial delivery of Melphalan HydrocholorideNCT01688401I/IIIVPediatricsVEGFRecurrent/refractory CNS tumorsMebendazole + vincristine, carboplatin, and temozolomideNCT01837862I/IIPOPediatricsKinase pathwayLGG, HGGTrametinib +/- DabrafenibI/IIPediatricsMAPK pathwayRelapsed/refractory cancerNivolumab +/- IpilumumabNCT03130959IIPOPediatricsYoung AdultsEpigenetic modulationHigh grade CNS tumorsNimotuzumabII/IIIPediatricsDMGRadiationFinding maximum dose of reirradiationNCT02709226I/IIPOPediatricsTargeted DNA damageDMGHypofractionatedRadiotherapyNCT05077735IIExternal beam radiationPediatricsDNA damageDMGRe-irridation of progressive orrecurrent DMGIIPediatricsAdultsTargeted DNA damageDMGRe-irradiation versus RT and Multiple elective RT coursesNCT03620032IIPOPediatricsYoung AdultsTargeted DNA DamageDMGVaccinesImmune Modulatory DC VaccineNCT03914768IPOPediatricsAdultsTargeted kinase pathwayGBMDMGImage-Guided TherapyCED of 124I-omburtamabNCT01502917ICEDPediatricsChemotherapyDMGCombinationBevacizumab +/- temozolomide +/- irinotecanNCT01114555I/IICEDPediatricsCytotoxic Drug DeliveryDMGHGGIndoximod + TemozolomideNCT04049669I/IIPOPediatricsTargeted TherapyDMGRecurrent/refractory CNS tumorsIrinotecan Liposome Injection using real time imaging w/ gadoliniumNCT03088813ICEDPediatricsLocal Drug DeliveryDMGLenalidomide + radiationNCT01226940IIVPediatricsChemotherapyDMG, HGGTemozolomide + radiationNCT05009992I/IIIV ± image-guidedPediatricsDrug delivery/RadiosensitizationDMGValproic acid, radiation, and bevacizumabNCT00879437IIIVPediatricsCytotoxic ChemotherapyDMG, HGGVandetanib + Dasatinib + radiationNCT00996723IIVPediatricsChemotherapyDMGVorinostat + radiationNCT01189266I/IIPOPediatricsKinase inhibitionDMGMindfulness-based InterventionNCT05336916N/AIVPediatrics, Young AdultsImmunotherapy/checkpoint modulationDMGHigh risk cancersHGG (high grade glioma) | MB (medulloblastoma) | GBM (glioblastoma multiforme) | NHL (Non-Hodgkin Lymphoma) Summary of Ongoing and Completed Clinical Trials including DMG Patients [86, 87] Detailed description of the therapeutic/trials, including phase, ClinicalTrials.gov identifier, administration, mechanism, & indication DMG, Recurrent/refractory CNS tumors Pediatrics Young Adults DMG Recurrent/refractory CNS tumors Pediatrics Young Adults B7-H3 EGFR806 HER2 IL13Rα2 DMG, Recurrent/refractory CNS tumors Pediatrics Young Adults Pediatrics Young Adults Pediatrics Young Adults Pediatrics Young Adults Pediatrics Adults Pediatrics Young Adults Pediatrics Young Adults DMG Solid brain/spinal tumors DMG HGG Pediatrics Young Adults DMG, Medulloblastoma, HGG Pediatrics Young Adults DNA damage/ PARP pathway DMG, Recurrent malignant CNS tumors Pediatrics Young Adults MAPK/ MEK pathway DMG Recurrent neuroblastoma Savolitinib (PBTC49) DMG, Medulloblastoma HGG Pediatrics Young Adults Pediatrics Young Adults CNS tumors Meningiomas Pediatrics Young Adults Pediatrics Young Adults Drug delivery enhancement radiosensitization Pediatrics Adults Solid tumors, NHL Histiocytic disorders Stereotactic Biopsy Split-Course Radiation Therapy Intradermal/ subQ Pediatrics Young Adults Medulloblastoma Grade III or IV gliomas SurVaxM (PBTC-060) Pediatrics Young Adults Pediatrics Young Adults Pediatrics Young Adults Pediatrics Young Adults Relapsed/refractory solid tumors Neuroblastoma Pediatrics Young Adults Pediatrics Young Adults HGG, Ependymoma DMG Pediatrics Young Adults Pediatrics Young Adults HGG DMG Pediatrics Young Adults Progressive brain tumors DMG Pediatrics Young Adults Pediatrics, Young Adults DMG HGG DMG HGG Immune checkpoint inhibition/ T-cell activation DMG Recurrent/progressive HGG Pediatrics Young Adults DMG HGG Pediatrics Young Adults Immune checkpoint/ cytokine modulation Pediatrics Adults Pediatrics Young Adults Hypofractionated Radiotherapy Re-irridation of progressive or recurrent DMG Pediatrics Adults Pediatrics Young Adults Pediatrics Adults GBM DMG DMG HGG DMG Recurrent/refractory CNS tumors Drug delivery/ Radiosensitization DMG High risk cancers HGG (high grade glioma) | MB (medulloblastoma) | GBM (glioblastoma multiforme) | NHL (Non-Hodgkin Lymphoma) Preclinical investigation of targeted strategies As the primary driver of DMG, the H3K27M mutated oncohistone protein triggers widespread epigenetic reprogramming by binding to and inhibiting the Polycomb Repressive Complex 2 (PRC2) methyltransferase. This inhibition leads to a drastic reduction in repressive H3K27 trimethylation (H3K27me3), while concurrently inducing an aberrant increase in H3K27 acetylation (H3K27ac) that activates silenced oncogenes. To counteract this, the HDAC inhibitor Panobinostat functions as a targeted therapy, reversing the disrupted landscape by restoring H3K27 trimethylation and reducing tumor-promoting effects [88–90]. Current pre-clinical research is focused on more effective strategies for treating DMG by targeting the mutated histone H3. Synergistic antitumor effects that prolonged survival in mice were observed when Panobinostat was combined with GSKJ4 (a drug that prevents the demethylation of the mutated H3 histone) [91] and CBL0137 (a compound promoting chromatin transcription and DNA repair) [92]. Strategies targeting activating mutations in activin A receptor type I (ACVR1), found in over 30% of DMG, have shown promise. ACVR1 encodes the serine/threonine activin receptor-like kinase-2 (ALK2), which is vital for tumorigenesis [57]. Targeting ALK2 with the pyrazolo[5-a]pyrimidine ALK2 inhibitor, LDN-193,189, and the pyridine derivative, LDN-214,117 demonstrated in vivo efficacy, significantly prolonging survival in mice with brainstem xenografts of H3K27M and ACVR1 mutated DMG cells [93]. The dual MEK1/2 and ACVR1 inhibitor, E2601 reduced viability of DMG cells carrying ACVR1 mutation and also extended survival in genetically engineered mice developing spontaneous ACVR1 mutated brainstem gliomas [94]. ACVR1 mutations induce varying effects on in vitro proliferation and survival. DMG cell lines carrying the highly potent ACVR1 R206H mutation were sensitive to the ACVR1 inhibitor LDN212854, and treatment with this inhibitor improved survival in mice [19]. A distinct, less common subtype of H3 K27-altered DMG exists in patients with wild-type H3, characterized by the overexpression of EZHIP. It functions as an oncohistone mimic and intrinsic inhibitor of PRC2, leading to a consequential loss of H3K27me3. This finding establishes EZH2 as a viable therapeutic target. EZH2 inhibitors prevent tumor growth via the activation of the p16 tumor suppressor protein [95]. Preclinical in vivo studies have supported the tumor-suppressive effects of EZH2 inhibitors [96], although research remains ongoing to better understand the impact of EZH2 monotherapy. Protein Kinase C (PKC) is a key regulator of cell growth, differentiation, and survival, and its activation promotes aggressive tumor cell behavior. Inhibition of the PI3K pathway in H3 K27-altered DMG produces compensatory activation of PKC signaling, fueling tumor survival and resistance. To overcome this, a therapeutic strategy supporting dual blockade was investigated for DMG by combining Paxalisib (an investigational small molecule that inhibits the PI3K pathway) with the PKC inhibitor, Enzastaurin to achieve a synergistic effect. Despite moderate BBB penetration (> 50%) of Paxalisib, and limited efficacy (15–17%) Enzastaurin, the combination extended mouse survival by 22% [74]. These findings highlight the need for superior BBB-permeant PKC inhibitors to optimize this combination strategy. Resistance to radiotherapy in DMG is partly driven by the tumor’s hypoxic environment. To overcome this, therapeutic strategies have employed diverse radiosensitizers designed to enhance tumor sensitivity while sparing surrounding healthy tissue [97]. One promising approach involves repurposing compounds such as the BBB-permeable lipophilic diabetes drug, phenformin, to inhibit mitochondrial oxygen consumption within tumor cells. Phenformin was additionally combined with dichloroacetate (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, to mitigate phenformin-induced lactic acid accumulation, thus increasing tumor metabolic stress and sensitivity to radiation. Although this pre-clinical investigation resulted in treatment-limiting weight loss in an orthotopic murine model, further dose optimization or development of alternative mitochondrial inhibitors for use with PDK blockade represent potential next steps toward improved radiosensitization [98]. The combination of anti-parasitic drugs and radiotherapy has also been suggested as novel approach towards the management of DMG and improve patient survival outcomes. Increasing evidence of the role of anti-parasitic drugs in inducing mitochondrial dysfunction and activating DNA damage pathways, makes them attractive candidates for repurposing them to enhance radiosensitivity in DMG [99]. Principles of nanoparticle-based tumor therapy Nanoparticles (NPs), defined as particles under 100 nm in diameter, are established cancer therapies with potential for treating DMG [100, 101]. The therapeutic promise of nanoparticle-based drug delivery lies in in two key mechanisms: passive accumulation via the Enhanced Permeability and Retention (EPR) effect, driven by leaky tumor vasculature, and Active Transport and Retention (ATR) or Enhanced Transcytosis and Retention (ETR), which utilize cellular transcytosis to cross endothelial barriers [102]. By optimizing particle size and surface modifications to trigger receptor-mediated transcytosis, nanoparticles can preferentially accumulate in tumor tissues while limiting diffusion into healthy organs, thereby reducing systemic toxicity [103]. The ATR principle offers a framework for engineering NP trafficking (entry, exit, and retention) in BBB-intact tumors like DMG [104]. NPs must be sufficiently small to avoid capture by the reticulo-endothelial system, but large enough to escape filtration by the kidneys. Achieving optimal particle size can therefore prolong retention time within the bloodstream or the tumor. Increasing the circulation time of NPs is critical for many applications, including drug delivery [105]. The surface conjugation of NP with polyethylene glycol (PEG) is an established strategy to increase persistence in circulation. By generating a neutral surface charge, PEGylation creates a “stealth” effect that camouflages the NPs from detection and rapid clearance by the immune system [76]. While extending the half-life of NP in vivo this process improves NP solubility and facilitates the attachment of specific targeting ligands [106]. Significant adaptability of nps for biomedical applications The inherent adaptability of nanoparticles makes them highly promising for a range of biomedical applications, including drug delivery systems, advanced imaging, and guided therapeutic interventions [107]. Their physical and chemical properties can be precisely engineered to promote biocompatibility and enhance retention in specific tumor tissues [108]. This is achieved through several key modifications including: (i) Targeting and co-delivery: Their small size and high surface-area-to-volume ratio allows for conjugation with multiple ligands for ultra-specific targeting and the simultaneous encapsulation of multiple drugs [109]. (ii) Controlled release: Coatings of acids and polymers can control the release of therapeutics, delivering drugs optimally in the acidic environment of tumors [110]. (iii) Enhanced retention: Adjusting the size and shape of nanoparticles can enhance cellular retention and influence permeability within tumors [105]. (iv) Improved drug properties: Modification can also improve the solubility of chemotherapeutics and control their release kinetics. (v) Imaging capabilities: In addition to therapeutic delivery, nanoparticles can be conjugated with fluorophores or manufactured with magnetic properties to enable fluorescent or magnetic resonance imaging [101, 108]. This section explores how NPs are revolutionizing medicine through their use in optimized delivery methods, advanced diagnostics, novel imaging techniques, and drug repositioning. Delivery and safety NP delivery methods can be optimized for specific applications and to avoid toxicity. For example, biodegradable and biocompatible liposomal nanoformulations can be administered intravenously, intraperitoneally, subcutaneously, or topically [101]. Topical administration offers an alternative to avoid systemic toxicities by preventing them from entering the bloodstream [111]. Diagnoses Beyond therapeutics, NPs are widely used for diagnostics [73]. For instance, they are commonly employed in biosensing assays to accurately detect the presence of various antigens in ex vivo patient samples in a noninvasive, accurate, and cost effective manner [112]. Their ability to conjugate with other molecules enhances signal sensitivity, enabling the detection of biomarkers for diseases, metabolic conditions, thromboses, pulmonary embolisms, and various cancers in both urine and blood samples [101]. Contrast agents for imaging NPs show promise as agents for guiding imaging platforms [113]. Surgical resection is a primary treatment for many cancers, but incomplete tumor removal and subsequent recurrence are common due to the difficulty in accurately identifying tumor margins [114]. NPs designed to target and accumulate at tumor sites, are used as contrast agents to better delineate a tumor’s exact location [113] Iron oxide, silica, and gold NPs have demonstrated success in enhancing tumor detection sensitivity using various techniques, including Computed Tomography (CT), Positron Emission Tomography (PET), magnetic resonance and fluorescence imaging, for both pre-operative and intra-operative use. Finally, these similar mechanisms also allow for the evaluation of treatment response by tracking tumor shrinkage following therapy [101, 115]. Repositioning Nps - from first-approved doxil to the future of cancer therapy The repurposing of nanomedicines, exemplified by the evolution of Doxil, demonstrates a powerful strategy for expanding the therapeutic applications of existing drugs in oncology. Doxil, a liposomal nanoparticle encapsulating doxorubicin, was initially approved for Kaposi’s Sarcoma but has since been repurposed and gained FDA approval for a wider array of cancers, including ovarian cancer and multiple myeloma [101]. The success of Doxil has paved the way for further innovation, with 13 different nanoparticle formulations now FDA-approved for various types of cancer. These advanced treatments include targeted therapies for breast cancer, pancreatic cancer, and acute lymphoblastic leukemia, illustrating how the strategic use of nanoparticles has broadened the therapeutic landscape for oncology [116, 117]. The continued development and repurpose of nanoparticle formulations promise more targeted and cost-effective path to new treatments. Nanoparticle formulations for targeted and sustained drug delivery in brain tumors .NPs are a promising strategy for enhancing CNS drug delivery, designed to circumvent the therapeutic limitations of the BBB. While the BBB restricts most small molecules, functionalized NPs that are PEGylated—can evade rapid immune clearance to achieve prolonged circulation times. This improved pharmacokinetic profile allows NPs to accumulate at the brain tumor site, leveraging the compromised vasculature of the blood-tumor barrier (BTB) through the EPR effect or active mechanisms like transcytosis and interaction with the TME (tumor-associated endothelial cells) via ATR/ETR route. Furthermore, these platforms can be decorated with ligands to specifically target tumor cells, enhancing penetration into the brain parenchyma [106]. Below, we summarize categories of brain-penetrating NPs for use in diagnosis and treatment of brain tumors (Fig. 5) and research findings that show improved drug delivery with less toxicity. Fig. 5Schematic of Multifunctional nanoplatforms for Brain Tumor Diagnosis and Therapy. The figure illustrates the advantages and multimodality of various nanoplatforms (organic, inorganic, and carbon-based) for brain tumor management. Their structural and functional composition post-functionalization with polyethylene glycol (PEG) allows the NPs to traverse the blood-brain barrier (BBB), while active targeting moieties facilitate specific accumulation in tumor cells for combined diagnostic and therapeutic applications Schematic of Multifunctional nanoplatforms for Brain Tumor Diagnosis and Therapy. The figure illustrates the advantages and multimodality of various nanoplatforms (organic, inorganic, and carbon-based) for brain tumor management. Their structural and functional composition post-functionalization with polyethylene glycol (PEG) allows the NPs to traverse the blood-brain barrier (BBB), while active targeting moieties facilitate specific accumulation in tumor cells for combined diagnostic and therapeutic applications Inorganic NPs Typically features a solid core of metallic (e.g., gold and silver) or metal oxide (e.g., iron oxide and gadolinium oxide) material. While metallic NPs are often synthesized through chemical reduction in the presence of a capping ligand, metal oxide NPs are produced using different chemical methods, such as co-precipitation [118]. Iron oxide nanoparticles (IONPs) are frequently used for brain imaging and targeted gene/drug delivery due to their inherent biocompatibility, biodegradability, adaptable surface chemistry for bioconjugation, and distinct magnetic characteristics. Superior therapeutic effects and low systemic toxicity have been demonstrated with the use of IONPs to co-deliver cisplatin and glutathione peroxidase-targeting siRNA for combinatorial GBM therapy [119]. A similar IONP system was developed for the targeted delivery of siRNAs to overcome drug resistance mediated by the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) during temozolomide therapy in GBM. This system effectively overcame biological barriers, specifically bound to tumor cells, and reduced MGMT expression in mouse models bearing patient-derived GBM xenografts [120]. Time-resolved MRI assessment demonstrated that chlorotoxin-conjugated IONPs facilitated efficient convection-enhanced delivery and specifically targeted cancer cells in a human glioblastoma mouse model [121]. However, many of these preclinical studies demonstrating therapeutic efficacy are based on GBM models rather than DMG, highlighting a current gap in DMG-specific research. Gold nanoparticles (AuNPs) have been explored for treating gliomas through several approaches. PEGylated AuNPs were able to successfully deliver doxorubicin to glioma cells by targeting the overexpressed LRP1 receptor, leading to significantly prolonged survival in mice [122]. In separate applications, the light-absorbing properties of AuNPs have been leveraged for photothermal therapy, with multiple studies exploring their conjugation with photosensitizers like integrins and silicon phthalocyanine [100, 123]. For theranostic and adjuvant applications, coupling of AuNP with ionizing radiation has demonstrated increased cellular DNA damage in GBM, boosting survival and reducing systemic toxicity from high-dose radiation This radiosensitization effect is primarily mediated by the high atomic number of gold, which enhances the photoelectric effect and generates secondary electrons that amplify localized DNA damage within tumor cells [124, 125]. However, the non-biodegradability of AuNPs remains a key challenge, prompting research into alternative methods of administration, including topical, intrarectal, and oral routes, to mitigate systemic toxicity concerns [101, 126]. Silver nanoparticles (AgNPs) have shown significant promise for treating GBM, primarily through the release of silver ions that induce DNA damage and disrupt membrane permeability by producing reactive oxygen species [127]. The ability of smaller AgNPs to infiltrate nuclear pores and cause chromosomal aberration further contributes to their therapeutic effects [127]. Like gold, AgNPs can act as effective radiosensitizers [128]. Numerous studies have demonstrated the benefits of AgNPs in promoting apoptosis and autophagy, enabling radioenhancement in the treatment of GBM [108, 129, 130]. Additionally, AgNPs exhibit similar therapeutic enhancement in both photo- and thermal-based treatments [131, 132]. However, concerns regarding potential toxicity remain, as AgNPs can induce oxidative stress and damage in healthy neural tissue, necessitating rigorous dose optimization and biocompatibility assessments [113]. Copper Nanoparticles (CuNPs) have emerged as versatile, cost-effective agents for antitumor therapy over the past decade. Leveraging their unique physicochemical properties, functionalized CuNPs effectively traverse the BBB to treat neurological tumors. They induce selective cancer cell death via cuproptosis—a copper-dependent form of oxidative stress—while their high surface-area-to-volume ratio optimizes drug delivery and photothermal therapy (PTT). Furthermore, their rapid clearance minimizes off-target toxicity, highlighting their potential as a highly selective theranostic platform [133–136]. Organic NPs are nanostructures composed of amphiphilic molecules that self-organize into spherical shapes in an aqueous environment. This process is driven by the molecules’ dual nature, which includes a water-loving (hydrophilic) and a water-hating (hydrophobic) part. This unique self-assembly property makes organic NPs valuable for applications like targeted drug delivery. This category includes micelles, liposomes, polymeric NPs, and dendrimers [137]. They are noted for their biocompatibility, biodegradability, and ability to enable controlled drug release making them ideal for neuro-oncologic applications like drug delivery [138]. Liposomes are spherical vesicles made of one or more phospholipid bilayers that enclose an aqueous core and are a promising strategy for delivering drugs to brain tumors. By exploiting the tumor’s leaky vasculature, these nanocarriers passively accumulate through the EPR effect and are retained longer due to poor lymphatic drainage [139]. However, for more effective targeting, liposomes can be functionalized for active targeting. This involves conjugating ligands to the liposome’s surface that can bind to receptors overexpressed on cancer cells or the cells of the BBB via ATR effect. Examples of these targeting ligands include transferrin, insulin, and endothelial growth factor. This receptor-mediated endocytosis facilitates the liposomes’ passage across the BBB [140, 141]. A notable challenge for systemically administered liposomes is their rapid uptake by the reticuloendothelial system (RES), primarily in the liver and spleen, which can diminish their therapeutic effect. This can be addressed through modifications like PEGylation [142]. Further advances include targeted therapies using specific receptors. For example, the development of high-density lipoprotein mimicking liposomal NPs to target the scavenger receptor class B type 1 (SCARB1) on medulloblastoma cells. This approach was shown to reduce tumor cell proliferation [143]. Polymer-based NPs are a promising strategy for delivering therapeutics to brain tumors due to their modifiable formulations. Poly(lactic-co-glycolic acid) (PLGA), an FDA-approved, biodegradable, and biocompatible polymer, is frequently used for this application because of its straightforward synthesis [144]. In one study, morusin-loaded PLGA NPs were conjugated with chlorotoxin, a peptide derived from scorpion venom to specifically target chloride channels on glioma cells, which led to significant cell death in multiple GBM cell lines [145]. Polyanhydride is another polymer commonly used in cancer therapy, notably in the FDA-approved Gliadel wafer for local chemotherapy in GBM. Emerging research indicates that polyanhydrides can cross the BBB, suggesting that combining NPs with Gliadel wafers is an exciting avenue for future development [146]. Furthermore, biodegradable poly (β-amino ester) (PBAE) NPs have recently shown merit in delivering the Herpes simplex virus I thymidine kinase suicide gene to medulloblastoma and atypical teratoid/rhabdoid tumors. This treatment resulted in high levels of gene transfection with substantial cell death in these cancer cell lines and significantly enhanced survival in mice bearing orthotopic tumor xenografts [147]. Dendrimers are organic NPs defined by a central core attached to symmetrical, branching structures with functional groups on their surface. For brain tumor targeting, conjugations with transferrin and EGFR are common, a strategy also seen with other organic NP formulations [128]. Poly-amidoamine (PAMAM) is the most frequently synthesized dendrimer, and studies have investigated how different conjugations can increase its diffusion into the CNS tissue [148]. Though EGFR-conjugated PAMAM dendrimers encapsulating doxorubicin increased drug delivery in glioma-bearing mice, in vivo translation has yet to provide convincing results [149, 150]. Polymeric micelles are self-assembled amphiphilic copolymers that show significant promise—and in certain preclinical contexts, superior performance to other nanocarriers—due to their small size and structural stability. Although they may have lower drug-loading capacities than other carriers, they demonstrate an exceptional ability to encapsulate hydrophobic drugs, offering high solubilization and easy, low-cost preparation [151–153]. Carbon-based NPs, including carbon nanotubes (CNTs), carbon dots (CDs), fullerenes, and graphene oxide (GO), have shown promise for treating brain cancer in preclinical studies. These NPs cross the BBB, deliver therapeutics directly to tumors, and can be modified for specific treatments like chemotherapy and phototherapy. Recent studies highlight promising results for Carbon-based NP-based targeted delivery to CNS. Carbon nanotubes (CNTs) are cylindrical, hexagonal-lattice carbon structures that are being investigated as a highly promising platform for brain-targeted drug delivery. Their unique properties, such as high surface area, biocompatibility, and ability to be tailored through functionalization make them ideal for carrying diverse drug payloads. Furthermore, optimized functionalization strategies enable them to cross the BBB efficiently [154]. A mechanical approach has been developed for the treatment of chemoresistant GBM in the mouse cortex. This method utilizes magnetic CNTs functionalized with an anti-CD44 antibody. The functionalized CNTs specifically target GBM cells—which are enriched with the CD44 antigen on their surface—and treat them with elevated efficacy upon the application of an external magnetic field [155]. This approach may also be applied to inoperable brain tumors such as DMG. Carbon dots (CDs) represent a new class of fluorescent, zero-dimensional carbon nanomaterials, characterized by their small size, typically under 10 nm. This carbon-based modality offers numerous advantages, including low production costs, high reproducibility, and the ability to be robustly modified for specific molecular targeting. This tunability allows for imaging and targeted drug delivery, which can minimize peripheral toxicity in cancer treatment [156]. Conjugating CDs with transferrin was shown to enable the formation of strong covalent bonds with chemotherapeutic drugs like doxorubicin, enhancing their delivery to various brain tumor cell lines [157]. Similarly, the benefits of this strategy were reinforced by showing that transferrin-targeting carbon nitride dots (CNDs) markedly enhanced the delivery of gemcitabine to pediatric glioma cells. CNDs are a type of CD that incorporates nitrogen atoms in their structure to improve their fluorescent properties [158]. This enhancement was observed when compared to delivery by non-functionalized NPs or gemcitabine administered alone. Graphene oxide (GO)— a novel, single atomic-thickness, two-dimensional carbon nanomaterial derived from graphene with promising applications in glioma treatment. Due to its exceptional physical and chemical properties, GO is being explored for four main applications in glioma treatment: direct killing, drug delivery, immunotherapy, and phototherapy. However, concerns regarding neurotoxicity and oxidative stress have been reported in preclinical studies, highlighting the need for further investigation into its safety profile before clinical translation [159–161]. Fullerenes (C60) excel as photosensitizers in photodynamic therapy (PDT) and reactive oxygen species (ROS) generation, facilitating superior tumor-specific apoptosis compared to graphene or nanotubes [162–164]. Beyond directly inducing apoptosis, fullerene derivatives exhibit potent antiangiogenic properties by inhibiting vascular endothelial growth factor (VEGF). This makes them promising agents for glioma treatment, as they can reduce tumor vasculature while simultaneously protecting surrounding healthy brain tissue through their inherent antioxidant activity [165]. Nanoparticle-based theranostic approaches in brain cancer NPs have become commonplace in both oncologic and non-oncologic therapeutics; however, their application in diagnosing brain malignancies, such as DMG, remains limited. NP-based theranostic approaches, as depicted in Fig. 6, offer a versatile platform for simultaneous diagnosis, real-time monitoring, and treatment of brain malignancies. The deep-seated midline location of DMG within the brain presents exceptional diagnostic challenges, as performing a definitive biopsy in this critical area is inherently difficult and carries significant risks. Consequently, diagnosis typically relies on a combination of a child’s rapid neurological decline and characteristic MRI findings. A key difficulty, however, is that these symptoms and imaging results can overlap with other brain tumors, hindering accurate differentiation [166]. The aggressiveness of DIPG and the expansive nature of its invasion make delineating tumor margins especially difficult. Furthermore, while gadolinium is the most common contrast agent for MRI, its potential for nephrotoxicity limits its use in patients with renal impairment [167]. These concerns make the use of NPs for diagnostic purposes particularly compelling. The multi-modality of NPs—allowing for their utility in both diagnosis and therapy—is the most promising aspect of nanomedicine. This capability has led to the term ‘theranostics’, a powerful approach for improving drug delivery initiatives in brain cancer. Fig. 6Schematic Illustrating the Application of NP based approaches in Diagnosis and Therapy of Brain Malignancies. These include enhanced tumor contrast, improved margin delineation, multimodal imaging, and image-guided delivery of therapeutic agents. These integrated capabilities support more precise treatment and have the potential to improve outcomes while reducing systemic toxicity Schematic Illustrating the Application of NP based approaches in Diagnosis and Therapy of Brain Malignancies. These include enhanced tumor contrast, improved margin delineation, multimodal imaging, and image-guided delivery of therapeutic agents. These integrated capabilities support more precise treatment and have the potential to improve outcomes while reducing systemic toxicity Clinically, several nanoparticle-based platforms have already demonstrated theranostic potential, supporting their translational relevance. For instance, Ferumoxytol, an FDA-approved iron oxide NP (IONP), is widely used as an MRI contrast agent and has been repurposed for tracking tumor-associated macrophage activity and treatment response in brain tumors [168]. Similarly, liposomal formulations like Doxil (liposomal doxorubicin) highlight the feasibility of nanoparticle-mediated drug delivery in oncology [169]. While these clinically approved systems underscore the potential for integrating diagnostic imaging with therapeutic delivery, their translation to DMG remains limited. The distinct paramagnetic properties of magnetic nanoparticles (NPs) position them as valuable agents for magnetic resonance imaging (MRI). Their utility in cancer imaging and therapy has been demonstrated across multiple studies. One study highlighted the efficacy of targeted iron oxide NPs (IONPs), which accumulated in glioblastoma cells with nine times greater efficiency than their untargeted counterparts, facilitating optimal tumor imaging while minimizing uptake by healthy tissue. This system was also adapted for theranostic applications, leveraging the NPs to enable the hyperthermic treatment of tumors [170]. Expanding on this potential, multifunctional IONPs conjugated with an F3 peptide achieved a three-fold prolonged tumor transit time and doubled the contrast-to-noise ratio in rat glioma cells. The co-delivery of the photoactivated drug Photofrin within these NPs significantly increased survival rates relative to non-targeted or systemically administered Photofrin [171]. In a different application, ferumoxytol IONPs served as an MRI contrast agent to monitor monocyte infiltration into glioblastoma cells post-amphotericin B treatment, revealing a markedly amplified uptake of ferumoxytol by monocytes in the treated tumor environment [172]. Gold nanoparticles (AuNPs) can be chelated with gadolinium to extend their short half-life and facilitate tumor tissue targeting. This approach enhances the properties of both materials within a single nanoplatform. In one study, researchers conjugated AuNPs with a transactivator of transcription (TAT) peptide, which improved brain tumor imaging compared to free gadolinium alone. This approach also proved beneficial for encapsulating and delivering doxorubicin to glioma tumor cells [173]. A significant challenge with AuNPs is their nonbiodegradability, which has spurred investigations into non-systemic administration methods. For instance, topical administration of surface-enhanced Raman scattering (SERS) NPs rapidly delineated breast cancer tumor margins in excised tissue. The results from this method compared favorably with established techniques like flow cytometry and immunochemistry. While this specific application addressed breast cancer, it demonstrates how varied NP administration methods offer distinct advantages and overcome limitations associated with more traditional therapies [111]. NP imaging offers high versatility, extending to simultaneous use with multiple imaging modalities. To leverage this, a combined SERS and multispectral optoacoustic tomography (MSOT) system was developed. This system achieved highly precise tumor margin delineation in glioma-bearing mice using gold nanostars by capitalizing on the high resolution of SERS and the deeper penetration of MSOT [174]. In another approach, researchers created a multimodal system incorporating MRI, photoacoustic imaging, and Raman imaging. This method used SERS NPs to target glioblastoma tumors in mice, exploiting the complementary sensitivity and spatial resolution of each modality [175]. These findings underscore the broad applicability of AuNP imaging and the significant potential for integrating different systems to enhance tumor identification. While multimodal systems are a key focus, NPs also show promise in fluorescence imaging. Specifically, zirconium-labeled liposomal NPs facilitate passive targeting, leading to enhanced uptake and optimal PET imaging in breast cancer models [176]. A translational study using PET imaging of ⁶⁴Cu-labeled HER2-targeted liposomal doxorubicin demonstrated substantial variability in tumor accumulation in patients and showed that higher nanoparticle deposition correlated with improved therapeutic response, highlighting its potential as a theranostic platform [177]. In a separate study, researchers used fluorescently-labeled silver nanoplate clusters, conjugated with an F3 peptide, to target rat glioma cell types, achieving a contrast enhancement of over 90% [178]. Organic nanoparticles, despite lacking intrinsic magnetic properties, offer significant diagnostic capabilities. In photoacoustic imaging, organic materials are valuable because they contain chromophores that produce size-independent photophysical properties—a distinct advantage over size-dependent metallic particles. This allows for the creation of nanoparticles (NPs) of a similar size that produce various signal intensities and absorption wavelengths. The EPR/ATR effect facilitates the accumulation of fluorescent liposomes in brain tumors, enabling their use as contrast agents [179]. To address the shortcomings of common contrast dyes like cyanine—specifically their poor photostability and limited retention in tumor tissue—researchers are exploring their incorporation into organic NPs for cancer diagnosis [180, 181]. For instance, Yang et al. developed liposomal NPs with magnetic nanocrystals and a PEG/fatty acid copolymer, a design that minimized toxicity and enhanced imaging in various cancer cell lines [182]. CNDs, a new generation of carbon dots (CD) featuring nitrogen heteroatom doping in their structure, can emit in a wide range of wavelengths, enabling various uses in imaging studies. The development of CDs and CNDs as carriers for contrast agents, such as gadolinium, also offers a promising way to reduce the dosage and toxicity of these otherwise toxic or non-biocompatible substances [183, 184]. A novel PEGylated polymeric nanoplatform incorporating a photosensitizer has been developed and evaluated for its potential in tri-modal imaging (fluorescence, MRI, and photoacoustic) of brain tumors in a murine model [185]. Dendrimers have been similarly successful when conjugated with gadolinium and fluorescent dyes [186, 187]. While the potential for improved diagnostic accuracy via NPs in cancer detection—particularly in preclinical models—is well-documented, significant challenges to clinical implementation persist. Researchers still need to address critical issues regarding long-term toxicity, low hepatic clearance, and high variability in human tumor accumulation [188]. Nanomedicine for DMG: overcoming barriers with current strategies and prospects DMG presents unique and heightened challenges to effective treatment. Common to most brain tumors is the limited ability of therapeutics to cross the BBB, a problem particularly pronounced in DMG. Additional barriers, such as drug efflux transporters and anisotropic effects, further impede drug infiltration. Finally, the distinct TME of DMG is deficient in critical immune mediators (e.g., CD3 + and CD8 + T-lymphocytes and PD-1), making many immunotherapies ineffective. NPs may offer a viable solution by potentially surmounting these obstacles and providing selective targeting for both diagnostic and therapeutic applications. Despite this potential, NP-based DMG research is currently limited, largely overshadowed by studies on GBM and other high-grade gliomas [100]. While numerous DMG treatment strategies have been developed (Table 1), remarkably few—only three studies to date—have investigated NP-based therapies. The research includes: (i) NP formulations (apoferritin and liposomal) that encapsulate N(3)-propragyl analogue (N3P), a drug used to treat temozolomide resistant cancers, demonstrating significant increase in drug uptake and therapeutic efficiency compared to free N3P in DMG cell cultures [189]; (ii) Doxorubicin-loaded AuNPs showed potent in vitro cytotoxicity; however, their failure to produce a significant antitumor effect or improve survival in rat models indicated poor BBB penetration remains a major challenge [190]. (iii) Finally, Spherical nucleic acids (SNAs)—AuNPs functionalized with highly oriented small interfering RNA duplexes—were tested for targeting and inhibiting the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1), which is overexpressed in DMG cell lines [191]. This limited research suggests that leveraging the unique properties of NPs is a promising future direction. The specific advantages that nanotechnology offers for DMG treatment are highlighted below Molecular targeting Genetic studies have been instrumental in identifying potential gene targets in DMG. Recent large-scale genomic analyses have identified alterations in the retinoblastoma (RB) cell cycle regulatory pathway in approximately 20–30% of DMG cases, including CDK4/6 amplification, CDKN2A/B deletion, and RB1 mutations [26, 192–195]. Given that CDK4/6 inhibitors are already being investigated for other brain tumors, using NPs to enhance the delivery of these agents to DMG tumors represents a compelling treatment strategy. Other genomic analyses have revealed aberrations in PDGFRα and PARP1 expression within DMG biopsies [196], while inhibition of another cell cycle regulator, Wee1, has enhanced survival in DMG mouse models [197]. While the precise nature and prevalence of these mutations warrant further investigation, these examples highlight the potential efficacy of inhibiting key genes involved in DMG tumor proliferation and underscore the need for effective delivery agents, such as NPs, to ensure adequate targeting. A separate study using 3D co-cultures generated in vitro tumor tissue analogs and identified a set of 14 proteins/genes overexpressed in DMG cells. These were curated into a non-canonical oncogenic signaling pathway activated by tumor-stroma interactions. Nine of these—including STAT3, SOD2, CEBP, ITGA5, MVP, LGALS1, CLIC1, LGALS3, and VCAM1—showed significantly increased expression in GBM/glioma patient tissues compared to normal brain tissue. However, five of the candidate proteins from the 3D model (CEBPB, PLSCR1, COL6A1, TIMP1, and NFkB1Z) did not show significant expression changes in the GBM/glioma cohorts [198]. This suggests that DMG may possess molecular characteristics distinct from more general gliomas and GBMs, offering opportunities for more selective targeting with NPs. In addition, chlorotoxin, a peptide derived from scorpion venom, specifically targets cell surface receptors found on brain tumor cells. These receptors—including matrix metalloproteinase-2 (MMP-2) and several chloride channels, such as CLIC1—were also demonstrated to be overexpressed in DMG cells in vitro and in a 3D co-culture tumor-permissive microenvironment [198, 199]. Various studies, primarily conducted in GBM models, have demonstrated that NP drug formulations conjugated with chlorotoxin can promote anti-tumor effects in gliomas [145, 200–203]. Given recent studies investigating the prevalence of these receptors on DIPG cells, chlorotoxin-conjugated NPs are a promising strategy for specific and effective DMG tumor targeting. Finally, a recent study identified the upregulation of several potential immune targets on the surface of DMG cells. These include Cluster of Differentiation 27 (CD276), B7 homolog 3 protein (B7H3), Interleukin 13 alpha receptor 2 (IL-13Rα2), Human Epidermal Growth Factor Receptor 2 (HER2), Ephrin Type-A Receptor 2 (EphA2), and Ephrin Type-A Receptor 3 (EphA3) [204]. Improved drug retention and extended release In addition to targeted drug delivery, NP functionalization is a promising strategy for increasing drug half-life in the brain—a critical advantage for treating DMG. Functionalization with hydrophilic polymers, such as PEG, enhances half-life by preventing immunogenic clearance, which allows for extended retention of the drug at the tumor site. This prolonged exposure is significant for effectively treating the fast-growing and persistent cells of DMG and offers the potential for less frequent therapy administration [205–207]. For imaging purposes, gadolinium enhancement also extends the half-life of NPs [208]. Beyond functionalization, other factors affect half-life, including nanoparticle size—smaller NPs face rapid renal excretion, while larger ones are subject to phagocytosis via the complement system—as well as core components, surface charge, and targeting moieties [209–211]. Ongoing research focuses on optimizing NP design by modifying these variables to maximize half-life for improved DMG therapeutic strategies [212]. Furthermore, nanoparticle-based drug delivery is a transformative approach that provides a sustained, low-dose exposure of therapeutic agents to the TME. This strategy can be used for metronomic chemotherapy in DMG, leveraging the controlled release and EPR or ATR effect for preferential delivery. This minimizes systemic side effects and lowers the risk of developing drug resistance [213, 214]. Gold nanoparticles can be chelated to gadolinium to extend their normally short half-life and can be targeted to tumor tissue. Radiosensitizers Radiation therapy is the established standard of care for DMG and is initiated promptly following diagnosis. A significant risk associated with this treatment is the potential for collateral damage to healthy cells, a concern that is especially acute in the sensitive tissue of the brain [215]. For aggressive tumors like DIPG, a reduced radiation dose—aimed at protecting healthy tissue—lowers the probability of effectively neutralizing the cancer. NPs can overcome this limitation by providing multiple methods to enhance the effectiveness of radiation within DMG cells. Their inherent ability to specifically target tumors helps to minimize radiation-mediated damage to healthy tissue [216]. In addition, due to the EPR or ATR effect in the tumor tissue, NPs can increase radiotherapy-focused DNA damage and inhibit DNA repair [217, 218]. Crucially, NPs can serve multiple roles. They can function as delivery vehicles for radiosensitizing agents or as intrinsic radiosensitizers themselves, depending on their composition, design, and desired purpose [219]. Among various options, AuNPs are particularly effective in amplifying the absorbed radiation dose for treating brain cancer, due to their stability, biocompatibility, and high atomic number (Z = 79). Gold’s high Z makes it highly efficient at absorbing X-rays (radiotherapy) [220–222] or high-energy protons (proton therapy) [223]. This absorption causes the gold atoms to release secondary and Auger electrons, which induce localized, high-energy damage to adjacent cancer cells. This mechanism is a key principle of a cancer treatment strategy called ‘nanoparticle radio-enhancement’. Imaging/treatment response NPs hold an intriguing potential for more accurate and thorough cancer detection. Research has already demonstrated that various organic and inorganic NPs enhance tumor imaging for GBM, suggesting a promising role in detecting DMG. The tumor-targeting capabilities of NPs are especially vital for comprehensively delineating DMG tumor margins, which is critical due to the disease’s rapid spread throughout the brain [100, 224]. This rapid progression also amplifies the importance of theranostic applications, which can simultaneously deliver therapy and monitor treatment response. The continued development of these advanced imaging modalities offers a promising avenue for improving the prognosis of DMG patients. Improving drug delivery across the BBB Focused ultrasound (FUS) combined with intravenously administered microbubbles has emerged as a promising, non-invasive strategy to transiently and locally disrupt the BBB, thereby enhancing drug delivery to Diffuse Midline Gliomas (DMG) [225]. The technique relies on acoustic cavitation, in which oscillating microbubbles induce mechanical stress on endothelial tight junctions, creating reversible BBB permeability. Preclinical studies show this method significantly increases the accumulation of chemotherapeutics and nanoparticles, highlighting its synergy with nanomedicine [226–228] Furthermore, low-intensity pulsed ultrasound via skull-implantable devices has demonstrated successful BBB opening for agents such as albumin-bound paclitaxel, with promising early-phase trials in recurrent glioblastoma (GBM; NCT04528680) [229]. These studies confirm the safety and feasibility of FUS-mediated disruption as a complementary approach to overcome one of the most significant pharmacological barriers in DMG therapy. Conclusion Key lessons learned. Nanoparticle-based platforms hold significant potential to improve diagnosis and treatment of DMG, yet their translation is hindered by the unique biology of the disease. While preclinical drug delivery results are promising, the intact BBB, active efflux pumps, intratumoral heterogeneity and the diffusely infiltrative nature of DMG present major obstacles. To move from promising, small-scale results to tangible clinical impact, the field must prioritize tailored, multifunctional systems designed to actively cross the BBB and distribute uniformly within the infiltrating tumor. Furthermore, while the EPR effect is often cited as the primary mechanism for nanoparticle accumulation in solid tumors, it is increasingly recognized as highly heterogeneous. In the specific case of DMG, the BBB often remains intact or only partially compromised, resulting in low accumulation of conventional passive NPs. Therefore, benchmarking drug delivery requires moving beyond reliance on passive accumulation to prioritize active transport mechanisms or methods —such as focused ultrasound (FUS) or convection-enhanced delivery—to ensure therapeutic concentration within DMG lesions. Outlook and Future perspective. To successfully translate these strategies from bench to bedside, future research must focus on optimizing NP design to ensure superior BBB penetration and enhanced retention within the TME. Parallel to this, efforts should prioritize the development of targeted, stimulus-responsive theranostic platforms that utilize tumor-specific biomarkers for simultaneous, real-time monitoring of therapeutic efficacy. To maximize clinical impact, these NP systems must be integrated with the standard of care, radiotherapy, utilizing NPs as radiosensitizers to improve tumor control while minimizing off-target side effects. Finally, overcoming persistent translational challenges, specifically by addressing manufacturing scalability and successfully navigating the regulatory landscape for complex nanomedicines, remains crucial for clinical implementation. Ultimately, successful DMG therapy depends on a collaborative, multidisciplinary approach that combines advanced materials science with clinical and radiological oncology. By engineering delivery systems tailored specifically to the unique constraints of DMG, we can reshape the treatment from purely palliative care to precise, targeted interventions for pediatric patients.